Avicanna Inc. (TSX: AVCN)

Market Cap	35.27M
Revenue (ttm)	24.90M
Net Income (ttm)	-6.80M
Shares Out	110.22M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,500
Open	0.320
Previous Close	0.320
Day's Range	0.320 - 0.320
52-Week Range	0.200 - 0.600
Beta	1.31
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 31, 2025

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 87
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: AVCN

Financial Performance

In 2023, Avicanna's revenue was 16.79 million, an increase of 314.82% compared to the previous year's 4.05 million. Losses were -8.74 million, -40.67% less than in 2022.